Amoxiplus

Amoxiplus is an approved, marketed generic fixed-dose combination antibiotic developed and manufactured by Antibiotice. It contains amoxicillin, a beta-lactam antibiotic of the aminopenicillin class, and clavulanic acid, a beta-lactamase inhibitor. Amoxiplus is indicated for the treatment of various bacterial infections, including middle ear and sinus infections, respiratory tract infections, urinary tract infections, skin and soft tissue infections (including dental infections), and bone and joint infections, as well as for surgical prophylaxis. Amoxicillin works by binding to and inhibiting penicillin-binding proteins (PBPs), which disrupts bacterial cell wall synthesis and leads to cell lysis. Clavulanic acid acts as a suicide inhibitor of bacterial beta-lactamases, preventing the enzymatic degradation of amoxicillin and restoring its activity against beta-lactamase-producing resistant strains.

Brand names

Amoxiplus